Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF) (2014 - 2026)
Aclaris Therapeutics (ACRS) recorded quarterly Depreciation & Amortization (CF) of $102000.0 in Q1 2026, little changed quarter-over-quarter from $102000.0 in Q4 2025, and down 20.31% on a YoY basis from $128000.0 in Q1 2025.
Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $102000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 20.31% year-over-year to $102000.0; the TTM figure through Mar 2026 stood at $428000.0 (down 38.15% YoY), while the FY2025 annual figure was $454000.0, down 43.74% from the prior year.
- Depreciation & Amortization (CF) was $102000.0 for Q1 2026 at Aclaris Therapeutics, roughly flat from $102000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $243000.0 in Q1 2024 to a low of $102000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $177823.5 across 5 years, with a median of $193000.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) advanced 22.73% in 2024, then slumped 52.89% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $190000.0 in 2022, then gained by 20.0% to $228000.0 in 2023, then slumped by 37.28% to $143000.0 in 2024, then declined by 28.67% to $102000.0 in 2025, then changed by 0.0% to $102000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $102000.0 (Q1 2026), $102000.0 (Q4 2025), and $110000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | 102,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Sep 30, 2025 | 110,000.00 |
| Sep 30, 2025 | 110,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Dec 31, 2024 | 143,000.00 |
| Dec 31, 2024 | 143,000.00 |
| Sep 30, 2024 | 179,000.00 |
| Sep 30, 2024 | 179,000.00 |
| Jun 30, 2024 | 242,000.00 |
| Jun 30, 2024 | 242,000.00 |
| Mar 31, 2024 | 243,000.00 |
| Mar 31, 2024 | 243,000.00 |
| Dec 31, 2023 | 228,000.00 |
| Dec 31, 2023 | 228,000.00 |